Novartis pelacarsen trial fails; Royalty Pharma expects modest return

September 4, 2026 7:05 PM

Royalty Pharma plc (Nasdaq: RPRX) announced that Novartis' Phase 3 HORIZON outcomes trial for pelacarsen did not meet its primary ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found